Linganisha mbinu

	Kiwango cha Ubora wa Maisha wa Ugonjwa wa Psoriatic Arthritis (PsAQoL)	Kiashirio cha Shughuli za Ugonjwa wa Ankylosing Spondylitis cha Bath (BASDAI)	Kielezo cha Kazi cha Ugonjwa wa Ankylosing Spondylitis (BASFI)	Kiwango cha Shughuli za Ugonjwa Viungo 28 (DAS28)
Nyanja	Rumatolojia	Rumatolojia	Rumatolojia	Rumatolojia
Familia	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
Mwaka wa asili	1997	1994	1994	1995
Mwanzilishi	McKenna & Doherty	Garrett et al.	Calin et al.	Prevoo et al.
Aina	Patient-reported outcome (PRO)	Patient-reported outcome (PRO)	Patient-reported outcome (PRO)	Clinician-rated
Chanzo asilia	Soderlin MK, Bergman S. Psychometric properties of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument: Rasch analysis. Arthritis Care Research. 2011;63(11):1589-1595.	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.	Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology. 1994;21(12):2281-2285.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.
Majina mbadala	PsAQoL, PSAQoL	BASDAI, BAS-DAI	BASFI, BAS-FI	DAS28, DAS28-CRP, DAS28-ESR
Zinazohusiana	4	4	4	3
Muhtasari	The PsAQoL is a disease-specific patient-reported outcome measure of quality of life impact in psoriatic arthritis (PsA), a chronic inflammatory condition affecting joints and skin. Developed by McKenna and Doherty in 1997, PsAQoL comprises 20 items assessing the multidimensional impact of PsA on physical function, emotional well-being, work productivity, and social participation. PsAQoL captures the patient's lived experience of the disease, complementing clinical disease activity measures (CRP, joint counts) and providing a holistic view of treatment benefit in PsA research and practice.	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.	The BASFI is a patient-reported outcome measure of functional disability in ankylosing spondylitis (AS), assessing physical limitations in 10 common daily activities. Introduced by Calin et al. in 1994, BASFI measures the impact of AS on quality of life and functional capacity, complementing BASDAI (disease activity). While BASDAI reflects inflammatory burden, BASFI reflects the consequences of inflammation and spinal damage on a patient's ability to perform daily tasks. BASFI is used alongside BASDAI in AS management to capture both disease activity and its functional impact.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.